Inovio Pharma (INO) Misses Q4 EPS by 5c
Tweet
Share
E-mailGet Alerts INO Hot Sheet
Price: $1.24 +2.48%
EPS Growth %: +75.9%
Financial Fact:
Grant and miscellaneous revenue: 9.41M
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: +75.9%
Financial Fact:
Grant and miscellaneous revenue: 9.41M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Inovio Pharma (NASDAQ: INO) reported Q4 EPS of ($0.35), $0.05 worse than the analyst estimate of ($0.30). Revenue for the quarter came in at $8.5 million versus the consensus estimate of $5.95 million.
For earnings history and earnings-related data on Inovio Pharma (INO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Investing.com’s stocks of the week
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
